Novartis AG and Amgen Inc.: SG&A Spending Patterns Compared

SG&A Spending Patterns: Novartis AG vs. Amgen Inc.

In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, Novartis AG and Amgen Inc. have demonstrated distinct approaches to their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Novartis AG consistently allocated a larger portion of its budget to SG&A, peaking in 2018 with a 16% increase from 2014. In contrast, Amgen Inc. showed a more conservative growth, with a notable 31% rise in 2023 compared to 2014. This divergence highlights Novartis's aggressive market strategies versus Amgen's steady, calculated expansion. As the pharmaceutical landscape continues to shift, these spending patterns offer valuable insights into each company's priorities and market positioning. Understanding these trends can provide investors and industry analysts with a clearer picture of future growth trajectories.